Edition:
United Kingdom

Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

88.21EUR
2:54pm BST
Change (% chg)

€-0.44 (-0.50%)
Prev Close
€88.65
Open
€88.34
Day's High
€88.88
Day's Low
€88.12
Volume
1,336,924
Avg. Vol
2,427,773
52-wk High
€92.97
52-wk Low
€62.50

SASY.PA

Chart for SASY.PA

About

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including... (more)

Overall

Beta: 0.91
Market Cap(Mil.): €111,740.20
Shares Outstanding(Mil.): 1,260.46
Dividend: 2.96
Yield (%): 3.34

Financials

  SASY.PA Industry Sector
P/E (TTM): 24.41 13.60 17.41
EPS (TTM): 3.63 -- --
ROI: -- -6.97 -5.24
ROE: -- -6.44 -4.49

Germany's Merck gets EU backing for oral MS drug

FRANKFURT Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

12:50pm BST

Germany's Merck gets EU backing for oral MS drug

FRANKFURT, June 23 Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral multiple sclerosis (MS) drugs in Europe, six years after its first attempt to launch the cladribine pill failed.

12:48pm BST

BRIEF-Rosa & Co announces renewal of multi-yr research agreement with Sanofi

* Rosa & Co announces renewal of multi-year research agreement with Sanofi

20 Jun 2017

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

16 Jun 2017

Sanofi chief says U.S. Supreme Court ruling on biologics has 'immediate impact'

PARIS The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

16 Jun 2017

Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact"

PARIS, June 16 The U.S Supreme Court decision to speed access to copycat biologics drugs on Monday was expected but has an "immediate impact", Sanofi Chief Executive told Reuters.

16 Jun 2017

BRIEF-Parexel collaborates with Sanofi to advance use of wearable devices in life science industry

* Parexel collaborates with Sanofi to advance the use of wearable devices in life science industry

15 Jun 2017

Sanofi to invest further in biologics

PARIS Sanofi announced plans to invest 600 million euros ($673 million) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

14 Jun 2017

Sanofi to invest further in biologics

PARIS Sanofi announced plans to invest 600 million euros (527.87 million pounds) annually over the next two to three years in the field of biologics production, an area of strong growth potential.

14 Jun 2017

UPDATE 1-Sanofi to invest further in biologics

* plans annual spending of 600 mln eur in biotechnology production

14 Jun 2017

More From Around the Web

Earnings vs. Estimates